- Trials with a EudraCT protocol (194)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
194 result(s) found for: Antihypertensive Drug.
Displaying page 1 of 10.
| EudraCT Number: 2006-006981-40 | Sponsor Protocol Number: hypertension2006-006981-40 | Start Date*: 2007-05-03 | |||||||||||
| Sponsor Name:Cambridge University Hospitals NHS Foundation Trust jointly with University of Cambridge | |||||||||||||
| Full Title: Does the underlying haemodynamic abnormality determine response to antihypertensive therapy in patients with hypertension? | |||||||||||||
| Medical condition: Essential hypertension | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) EE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-003410-12 | Sponsor Protocol Number: RG_19-169 | Start Date*: 2020-12-16 |
| Sponsor Name:University of Birmingham | ||
| Full Title: Pregnancy ANtihypertensive Drugs: which Agent is best? | ||
| Medical condition: Hypertension in pregnancy (chronic hypertension, gestational hypertension or pre-eclampsia) | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: GB (GB - no longer in EU/EEA) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-001404-14 | Sponsor Protocol Number: QGC001-3QG2 | Start Date*: 2021-08-17 | |||||||||||
| Sponsor Name:Quantum Genomics | |||||||||||||
| Full Title: A Phase 3, Double-blind, Placebo-controlled and Open-label Efficacy and Long-term Safety Study of Firibastat (QGC001) Administered Orally, Once Daily, for Up to 48 Weeks in Patients with Difficult-... | |||||||||||||
| Medical condition: Treatment of patients with difficult-to-treat and/or treatment-resistant hypertension (HTN) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SK (Prematurely Ended) HU (Prematurely Ended) ES (Ongoing) CZ (Prematurely Ended) IT (Completed) NL (Prematurely Ended) BE (Completed) BG (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-002545-32 | Sponsor Protocol Number: CR0002 | Start Date*: 2019-11-06 | |||||||||||
| Sponsor Name:Ablative Solutions, Inc | |||||||||||||
| Full Title: A Pivotal, Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation by the Peregrine System™ Kit, in Subjects with Hypertension. | |||||||||||||
| Medical condition: Hypertension | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) SE (Ongoing) BE (Trial now transitioned) NL (Trial now transitioned) IE (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-004509-29 | Sponsor Protocol Number: QGC001-3QG1 | Start Date*: 2020-04-27 |
| Sponsor Name:Quantum Genomics | ||
| Full Title: A Phase 3, Double-blind, Placebo-controlled, Efficacy and Safety Study of Firibastat (QGC001) Administered Orally, Twice Daily, Over 12 Weeks in Difficult-to-treat/Resistant Hypertensive Subjects | ||
| Medical condition: Treatment of hypertension (HTN) in difficult-to-treat and/or treatment resistant patients | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Completed) DE (Completed) PL (Completed) ES (Ongoing) CZ (Completed) HU (Completed) BG (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2008-003535-20 | Sponsor Protocol Number: CS8635-A-E303 | Start Date*: 2009-04-07 | |||||||||||
| Sponsor Name:DAIICHI SANKYO EUROPE GmbH | |||||||||||||
| Full Title: A RANDOMISED, DOUBLE-BLIND, ADD-ON STUDY OF HYDROCHLOROTHIAZIDE IN SUBJECTS WITH MODERATE TO SEVERE HYPERTENSION NOT ACHIEVING TARGET BLOOD PRESSURE ON OLMESARTAN MEDOXOMIL/AMLODIPINE FIXED DOSE CO... | |||||||||||||
| Medical condition: Essential hypertension | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) NL (Completed) FR (Completed) BE (Completed) ES (Completed) AT (Completed) CZ (Completed) DK (Completed) SK (Completed) BG (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-002544-40 | Sponsor Protocol Number: 5866 | Start Date*: 2014-10-29 |
| Sponsor Name:Hôpitaux Universitaires de Strasbourg | ||
| Full Title: THE TREATMENT OF HYPERTENSION ASSOCIATED WITH SEVERE PREECLAMPSIA. A RANDOMIZED CONTROLLED TRIAL OF URAPIDIL VERSUS NICARDIPINE. The URANIC trial. | ||
| Medical condition: Hypertension associated with severe pre eclampsia | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: FR (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2011-005344-95 | Sponsor Protocol Number: 3004 | Start Date*: 2012-06-15 |
| Sponsor Name:Steno Diabetes Center | ||
| Full Title: Time course of the blood pressure lowering effect of liraglutide therapy in type 2 diabetes | ||
| Medical condition: type 2 diabetes | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DK (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2007-000631-25 | Sponsor Protocol Number: 2007-000631-25 | Start Date*: 2010-06-08 | |||||||||||
| Sponsor Name:KAROLINSKA INSTITUTET | |||||||||||||
| Full Title: THE ANTITTHROMBOTIC EFFECTS OF DOXAZOSIN AND RAMIPRIL IN ESSENTIAL HYPERTENSION | |||||||||||||
| Medical condition: ESSENTIAL HYPERTENSION | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2006-001898-25 | Sponsor Protocol Number: DAR-311 | Start Date*: 2006-09-21 | |||||||||||
| Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
| Full Title: DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Evaluate the Effica... | |||||||||||||
| Medical condition: Resistant hypertension | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) DK (Completed) DE (Completed) GB (Completed) ES (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-003547-23 | Sponsor Protocol Number: DAR-312 | Start Date*: 2007-11-15 | |||||||||||
| Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
| Full Title: DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension A Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-center, Parallel Grou... | |||||||||||||
| Medical condition: Resistant hypertension | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) GB (Completed) DE (Completed) BE (Completed) DK (Completed) ES (Completed) CZ (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-003647-28 | Sponsor Protocol Number: NA | Start Date*: 2020-12-09 |
| Sponsor Name: | ||
| Full Title: Differences in antihypertensive drug levels in patients with hypertension: old vs young 2 | ||
| Medical condition: Hypertension Cardiovascular disease | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2016-000165-23 | Sponsor Protocol Number: INFORM | Start Date*: 2016-10-19 | |||||||||||
| Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge | |||||||||||||
| Full Title: ComparIsoN oF Optimal Hypertension RegiMens (Part of the Ancestry Informative Markers in Hypertension (AIM HY) Programme – AIM HY-INFORM) | |||||||||||||
| Medical condition: Cardiovascular Hemodynamics | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-004212-21 | Sponsor Protocol Number: AMAG-423-201 | Start Date*: 2019-05-24 | |||||||||||
| Sponsor Name:AMAG Pharmaceuticals, Inc. | |||||||||||||
| Full Title: A Phase 2b/3a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of AMAG-423, a Digoxin Immune Fab, in Antepartum Subjects with Severe Pree... | |||||||||||||
| Medical condition: Severe Preeclampsia | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: PL (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) BE (Completed) RO (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-021988-32 | Sponsor Protocol Number: LUMI/10/ZOF- HYP/001 | Start Date*: 2010-09-27 | |||||||||||
| Sponsor Name:LUSOFARMACO | |||||||||||||
| Full Title: A multicentre, multinational, randomised, double-blind, pilot, ascending dose for non responder, parallel group study on the therapeutic efficacy and safety of o.d. Zofenopril 30 mg plus HCTZ 12.5 ... | |||||||||||||
| Medical condition: elderly subjects (age > 65 years) affected by Isolated Systolic Hypertension | |||||||||||||
|
|||||||||||||
| Population Age: Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-002920-10 | Sponsor Protocol Number: TRE-1486--0105-I | Start Date*: 2016-09-14 |
| Sponsor Name:Klinikum der Universitaet Muenchen AoeR | ||
| Full Title: TREAT-SVDs: EffecTs of Amlodipine and other Blood PREssure Lowering Agents on Microvascular FuncTion in Small Vessel Diseases | ||
| Medical condition: Cerebral small vessel disease | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended) GB (GB - no longer in EU/EEA) | ||
| Trial results: View results | ||
| EudraCT Number: 2008-003534-25 | Sponsor Protocol Number: CS8635-A-E302 | Start Date*: 2009-05-13 | |||||||||||
| Sponsor Name:DAIICHI SANKYO EUROPE GmbH | |||||||||||||
| Full Title: A randomised, double-blind, parallel group study evaluating the efficacy and safety of co administration of triple combinations of olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide... | |||||||||||||
| Medical condition: Essential hypertension | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: LV (Completed) DE (Completed) NL (Completed) ES (Completed) BE (Completed) CZ (Completed) DK (Completed) BG (Completed) SK (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-001562-16 | Sponsor Protocol Number: RGHT000278 | Start Date*: 2006-11-01 | |||||||||||
| Sponsor Name:Royal Group of Hospitals Trust | |||||||||||||
| Full Title: Studies of insulin action in patients at increased vascular risk. Modulation by antihypertensive and endocrine replacement therapy. | |||||||||||||
| Medical condition: Protocol (a): Essential Hypertension Protocol (b): Hypertension in Type 2 Diabetes Protocol (c): Panhypopituitarism | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-000605-12 | Sponsor Protocol Number: notapplicable1 | Start Date*: 2014-06-13 |
| Sponsor Name: | ||
| Full Title: Thiazide diuretics versus calcium channel blockers for the treatment of calcineurin inhibitor-induced hypertension in patients with psoriasis or eczema: a single-center randomized cross-over trial. | ||
| Medical condition: Hypertension, induced by the use of a Calcineurin Inhibitor (CNI) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2008-003568-20 | Sponsor Protocol Number: RGR | Start Date*: 2008-08-08 |
| Sponsor Name:Prof Alice Stanton | ||
| Full Title: Renin Genotype and Response to Renin Angiotensin System Blockade. | ||
| Medical condition: Hypertension | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: IE (Completed) | ||
| Trial results: View results | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.